Nemaura Medical (OTC:NMRD) said today that it has finished development of a medical grade app designed to be used with the company’s SugarBeat continuous glucose monitoring system or with glucose meters.
The mobile app, which was developed for android mobile devices, allows users to input their diet, medication and exercise information, as well as view glucose trends.
The England-based company said that development of an iOS version of the app is planned.
Nemaura’s SugarBeat device is a wireless, adhesive skin-patch that connects to a rechargeable transmitter and can be used as a non-invasive way for diabetics to monitor their blood glucose levels.
In August, the company said that it has finished development of a next-gen version of its SugarBeat CGM, which features a slimmer transmitter than its predecessor and a built-in, rechargeable battery.
Nemaura plans to launch clinical trials of its next-gen device soon and anticipates a launch in the UK later this year.